Three FDA-approved prescription medications contain THC or a close synthetic mimic of it: dronabinol capsules (sold as Marinol), dronabinol oral solution (sold as Syndros), and nabilone capsules (sold as Cesamet). Dronabinol is synthetic delta-9-THC, the same molecule found in cannabis, while nabilone is a slightly different synthetic compound designed to act on the same receptors. All three are approved for narrow medical uses, and their regulatory story reveals a lot about how the federal government draws the line between “illegal drug” and “prescription medicine.”
Dronabinol and Its Two Formulations
Dronabinol was the first THC-based drug to receive FDA approval. Marinol, the capsule form, was approved in 1985 for nausea and vomiting caused by cancer chemotherapy, then received a second approval in 1992 as an appetite stimulant for people with AIDS-related weight loss.1PubMed. Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications Both indications remain on the label today, and dronabinol is still the only FDA-approved medication that is chemically identical to the THC molecule produced by the cannabis plant.
Syndros, the oral liquid version of dronabinol, came along in 2016. It carries the same approved uses as Marinol but was designed to address a practical problem with the capsule. In pharmacokinetic testing, the liquid was absorbed much faster: all volunteers had detectable THC in their blood within 30 minutes of taking the solution with food, compared to only about 15 percent of those who took the capsule.2PubMed Central. Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers That faster, more predictable absorption matters when someone is actively nauseated and needs relief quickly.
A separate bioequivalence study confirmed that the solution and capsule deliver roughly the same total amount of dronabinol into the bloodstream over time, but the solution showed less person-to-person variability in overall exposure. In that trial, every participant had detectable plasma dronabinol within 15 minutes of taking the liquid, versus under 17 percent with the capsule.3PubMed Central. Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers For patients who are vomiting or who have trouble swallowing capsules, the liquid is a more reliable delivery method.
Nabilone and How It Differs from Dronabinol
Nabilone, marketed as Cesamet, is the third FDA-approved medication in this category, but it occupies a slightly different chemical space. Rather than being identical to plant-derived THC, nabilone is a synthetic compound engineered to mimic THC’s signaling at cannabinoid receptors.4PubMed. The State of Synthetic Cannabinoid Medications for the Treatment of Pain Think of it as a cousin molecule: similar enough to produce anti-nausea effects, but structurally tweaked in the lab. The FDA approved nabilone specifically for nausea and vomiting caused by cancer chemotherapy, and unlike dronabinol, it does not carry a separate approval for appetite stimulation in AIDS patients.
In practice, prescribers sometimes choose between dronabinol and nabilone based on side-effect profiles and individual patient response. Both can cause dizziness, drowsiness, and a mild “high,” but the intensity and character of these effects differ from person to person. Nabilone’s slightly altered structure means its metabolism follows a somewhat different path in the body, which can matter for patients taking other medications.
What About Epidiolex and Nabiximols?
People sometimes lump all cannabis-derived medications together, so it is worth clarifying which FDA-approved drugs do not contain THC. Epidiolex is an FDA-approved oral solution of cannabidiol (CBD) used for certain seizure disorders. CBD is a completely different molecule from THC, produces no intoxication, and works through different mechanisms. Epidiolex has no THC in it and belongs to a separate conversation.
Nabiximols (brand name Sativex) is the medication that confuses people most, because it does contain THC alongside CBD. It is delivered as an oromucosal spray and is approved in over 25 countries, including Canada, the United Kingdom, France, and Poland, for spasticity related to multiple sclerosis and for cancer-associated pain.5Remington (Twenty-third Edition). Medicinal : an overview for health-care providers It is not, however, approved in the United States, and clinical trials for US approval are still underway. So while nabiximols is a real, regulated THC-containing medication in much of the world, it does not appear on the FDA’s approved list.
What These Medications Are Approved to Treat
The approved uses for dronabinol and nabilone are narrow: chemotherapy-induced nausea and vomiting, and in dronabinol’s case, appetite loss and wasting in people living with HIV/AIDS. These are situations where standard treatments have often already failed or proved insufficient. A prescriber typically reaches for dronabinol or nabilone after first-line anti-nausea drugs have not done enough.
The evidence behind the appetite indication is concrete. In a study of 117 HIV/AIDS patients who had been losing weight, about 63 percent maintained or gained weight after starting dronabinol. Among those who stayed on it for a year, the average weight gain was roughly 3.7 pounds. Just as striking, the share of patients reporting loss of appetite dropped from 71 percent at the start of the study to 26 percent after one month and continued declining over time.6PubMed. Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients A longer-term study found that appetite improvement persisted, with visual analog scale scores for appetite consistently at least double the baseline value for at least seven months of continuous use.7Journal of Pain and Symptom Management. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia
For chemotherapy-induced nausea, a randomized trial comparing dronabinol, ondansetron (a widely used anti-nausea drug), their combination, and placebo found that nausea absence was significantly higher in all active treatment groups than with placebo. About 71 percent of dronabinol patients were nausea-free, compared to 15 percent on placebo, and dronabinol also showed the lowest nausea intensity and vomiting among the groups. The study was small enough that its authors cautioned against broad interpretation, but the direction of the effect was clear.8PubMed. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting
Off-Label Uses Under Investigation
Physicians can legally prescribe an FDA-approved drug for uses beyond its labelled indications, and dronabinol is prescribed off-label more often than some people realize. Two areas where researchers have shown the most interest are obstructive sleep apnea and agitation in Alzheimer’s disease.
For sleep apnea, there are currently no FDA-approved drug treatments at all. A phase II clinical trial (the PACE trial) tested dronabinol in people with moderate or severe obstructive sleep apnea after a smaller dose-escalation pilot study had shown early promise.9PubMed Central. Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea The idea is that cannabinoids may stabilize upper-airway muscle tone during sleep through effects on serotonin signaling in the brainstem. The research is still in relatively early stages, but the complete absence of drug alternatives for sleep apnea makes even preliminary findings noteworthy.
In Alzheimer’s dementia, researchers have explored whether dronabinol can reduce agitation, one of the most distressing behavioral symptoms for patients and caregivers alike. Early results presented at an international psychogeriatrics meeting found that the dronabinol group showed a statistically significant improvement in agitation scores compared to placebo, with minimal adverse effects and no drug interactions observed during the trial.10Tufts Medical Center. Study: Synthetic THC May Reduce Agitation in Patients with Alzheimer’s Dementia This is still considered preliminary, but it points toward a potential niche for THC-based medications in geriatric neuropsychiatry where current options are limited and often carry their own serious side effects.
Drug Interactions and Safety Concerns
Dronabinol is broken down in the liver primarily by two enzyme families, CYP2C9 and CYP3A4. Any other drug that competes for or blocks these same enzymes can change how quickly dronabinol is processed, potentially increasing its effects or making them last longer. The prescribing information for Marinol and Syndros acknowledges that the full interaction profile is not completely understood, which means there may be clinically significant interactions beyond what is currently documented.11Medical Cannabis and Cannabinoids. Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions Separate pharmacokinetic data confirm that CYP3A4 plays a central role in THC metabolism, and that strong inducers or inhibitors of this enzyme can significantly alter THC levels in the blood.12PubMed. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products
What this means practically: if you are taking dronabinol and your doctor adds or removes another medication that strongly affects CYP3A4 or CYP2C9, the dronabinol dose may need adjusting. Common CYP3A4 inhibitors include certain antifungal drugs and some antibiotics. Grapefruit juice, famously, also inhibits CYP3A4 and could theoretically increase dronabinol exposure, though this particular combination has not been well-studied in clinical trials.
The side effects that patients most commonly report are dizziness, drowsiness, euphoria (or sometimes its opposite, dysphoria), and difficulty concentrating. These are predictable given that the drug acts on the same brain receptors as cannabis. In the long-term AIDS wasting studies, the most frequent adverse events were related to these central nervous system effects, and the drug was generally well tolerated over months of continuous use.7Journal of Pain and Symptom Management. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia
Is There an Abuse Risk?
One of the more persistent questions about prescribing a THC-containing medication is whether patients will misuse it to get high. The pharmacological profile of oral dronabinol works against recreational abuse in several ways. Swallowed THC is absorbed slowly and undergoes extensive first-pass metabolism in the liver, meaning the onset of effects is gradual compared to smoking or vaping cannabis. A review of abuse potential found that dronabinol has slow onset, is at most weakly reinforcing, and that the overwhelming majority of user reports describe its effects as dysphoric and unappealing rather than pleasurable.13PubMed. Abuse potential of dronabinol (Marinol) In short, taking dronabinol is not the same experience as smoking cannabis, and most people who have tried both do not find the pill version recreationally satisfying.
That said, dronabinol is currently classified as a Schedule II controlled substance under federal law (Syndros is Schedule II; Marinol was rescheduled from Schedule II to Schedule III in 1999), and nabilone is Schedule II. These classifications reflect the DEA’s judgment about abuse liability and accepted medical use, and they affect how the drugs are prescribed and dispensed. Schedule II medications require a written prescription (no phone-in orders), cannot be refilled without a new prescription, and are subject to production quotas.
Dronabinol in Children and Older Adults
Dronabinol does not have specific FDA-approved pediatric indications, but it is used off-label in pediatric oncology settings for chemotherapy-induced nausea. A review of pediatric use found that 95 percent of children in the cohort were receiving moderate or highly emetogenic chemotherapy, and about 60 percent had a defined positive response to dronabinol. Interestingly, the vast majority (95 percent) received doses lower than reference guidelines suggest, which may reflect prescribers’ caution with a psychoactive drug in young patients. About 65 percent received repeat courses, suggesting that families and clinicians found it helpful enough to continue.14PubMed Central. Characterization of Dronabinol Usage in a Pediatric Oncology Population
In older adults, the same central nervous system side effects that are mildly annoying in younger patients become more concerning. Dizziness and cognitive effects increase the risk of falls, and older adults are more likely to be taking multiple medications that might interact with dronabinol’s metabolic pathway. The Alzheimer’s agitation research mentioned earlier is cautiously optimistic, but any expansion of THC prescribing in elderly populations will need to carefully weigh cognitive side effects against behavioral benefits.
Why Oral THC Does Not Feel Like Smoking Cannabis
People who have smoked or vaped cannabis and then tried prescription dronabinol often report that the experiences feel quite different. This is not surprising given the pharmacokinetics involved. Inhaled cannabis produces a rapid spike in blood THC levels, with peak concentrations that are high and variable. Oral THC, by contrast, results in low, delayed peak concentrations because the drug passes through the gut and liver before reaching the bloodstream, a process that substantially reduces how much active THC actually makes it into circulation.15PubMed Central. Human cannabinoid pharmacokinetics The liver also converts some of the THC into 11-hydroxy-THC, a metabolite that crosses into the brain more easily and produces somewhat different psychoactive effects than THC itself. This is why cannabis edibles in general feel different from smoked cannabis, and prescription dronabinol follows the same pattern.
This pharmacokinetic reality has implications for both efficacy and side effects. The slow onset means patients need to take dronabinol well before they expect to feel nauseated, not in response to active vomiting. It also means the effects last longer and are harder to titrate on the fly compared to inhaled routes. The development of the Syndros liquid was partly an attempt to speed up that absorption lag while maintaining the standardized dosing that a prescription product requires.
The Regulatory Paradox
The existence of FDA-approved THC medications creates a peculiar regulatory situation. The federal government classifies cannabis as a Schedule I substance, meaning it is officially considered to have no accepted medical use and a high potential for abuse. Yet dronabinol, which is the exact same molecule found in cannabis, is an FDA-approved medicine in Schedule II (or III, depending on formulation). The FDA’s approval pathway treats cannabis-derived or cannabis-mimicking compounds no differently from any other drug candidate: companies must run the same phases of clinical trials, meet the same manufacturing standards, and satisfy the same efficacy and safety bars.16Frontiers in Plant Science. Legal and Regulatory Issues Governing Cannabis and Cannabis-Derived Products in the United States
This means that the molecule itself is not the problem in the eyes of federal regulators. What matters is whether a specific product has gone through the formal approval process. A pharmaceutical company that produces synthetic THC in a controlled lab, runs clinical trials, and wins FDA approval ends up with a legal prescription drug. A plant that produces the same molecule in a field remains, federally speaking, a Schedule I substance. Whether you find this logically consistent or absurd probably depends on your perspective, but it is the framework that currently governs which THC products your doctor can legally write a prescription for.
Practical Considerations for Patients
If your doctor prescribes dronabinol or nabilone, a few practical realities are worth knowing. These medications are expensive. Without insurance, a month’s supply of dronabinol capsules can run several hundred dollars, and the oral solution is often more expensive than the capsule. Insurance coverage varies widely, and prior authorization is commonly required because the drugs are typically reserved for patients who have not responded adequately to other anti-nausea treatments.
You will also need to be aware that taking prescription THC can cause you to test positive on a standard urine drug screen. Employers, probation officers, and sports organizations rarely distinguish between THC from a legal prescription and THC from recreational cannabis use on a basic immunoassay test. If drug testing is part of your life, having a prescription on file and communicating proactively with whoever orders the test is important.
Storage can be a minor nuisance as well. Dronabinol capsules need to be kept in a cool environment because the active ingredient is dissolved in sesame oil and the capsules can soften or leak at higher temperatures. The oral solution has its own storage requirements and a limited shelf life once opened. Neither formulation is something you want to leave in a hot car.